VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May, 06 2021

BRIDGEWATER, N.J., May 06, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. “Our sales organization continues to drive utilization of AMZEEQ and ZILXI, with prescriptions for both products gaining momentum,” said David Domzalski, Chief Executive Officer of VYNE Therapeutics. “During the first quarter, we unveiled our newest candidate FMX114, a combination topical gel product candidate for the treatment of mild-to-moderate atopic dermatitis. We plan to take FMX114 into a Phase 2a study in the third quarter, with top-line…

Read More